Mind Medicine Australia

What Mind Medicine Australia does

Mind Medicine Australia (MMA) is a Melbourne-based registered charity, founded in 2019, that operates as a vertically integrated platform for psychedelic-assisted therapies (PAT) targeting treatment-resistant depression, PTSD, and other intractable mental health conditions. Its core offerings span the full ecosystem: the Certificate in Psychedelic-Assisted Therapies (CPAT) and Fundamentals of Psychedelic-Assisted Therapies online course for training clinicians; the MMA Clinic and an Authorised Prescriber network for direct patient treatment; the Patient Support Fund (PSF) for subsidizing treatment costs; and the PAT Research Registry hosted with the Australian National University for clinical trial coordination. The organization's technology foundation is clinical rather than software-based, centered on psilocybin and MDMA protocols administered by authorized psychiatrists under Schedule 8 controlled-medicine regulations.

MMA pursues a multi-channel go-to-market combining sales-led professional training, event-driven awareness (255+ events, International Summit on Psychedelic Therapies), and community-led engagement through lived-experience panels and a CPAT alumni directory. Its customer base is split across patient consumers (treatment-resistant depression, PTSD), healthcare professionals seeking certification (750+ clinicians across Australia, New Zealand, and globally), and institutional funders including the Australian Federal Government ($15M grant) and private foundations (Hunt Family Foundation, Perpetual). Revenue mechanics depend on charitable donations, CPAT training fees, online course tuition, and government grants, with a $2.5M Patient Support Fund-raising target underscoring the philanthropic funding model. MMA's strategic significance rests on its role as the architect of Australia's world-first rescheduling of psilocybin and MDMA, giving it outsized influence on the clinical, regulatory, and educational trajectory of psychedelic medicine in Australia.

Name

Mind Medicine Australia

Legal name

Mind Medicine Australia

Website

https://mindmedicineaustralia.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Mind Medicine Australia is a Melbourne-based registered charity that trains clinicians (750+ via CPAT), operates a psychedelic-assisted therapy clinic, and advocates for psilocybin and MDMA access for treatment-resistant depression and PTSD in Australia.

Ownership category

akta.pro rank

Product category

Mental Health Treatment & Psychedelic Therapy Training Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Educational Services (8200)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industry

Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Psychedelic-assisted therapies
• Mental health training
• Clinician certification programs
• Mental health advocacy
• Charitable health services

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

1. Charitable Donations: As a registered charity with the Australian Charities and NFPs Commission, MMA relies heavily on philanthropic donations from individuals, foundations, and organizations. The Patient Support Fund receives donations to subsidize treatment costs for patients who cannot afford full treatment.
2. Training Program Fees: Revenue from CPAT (Certificate in Psychedelic-Assisted Therapies) training program fees for mental health professionals seeking to become certified in psychedelic-assisted therapies.
3. Government Grants: Federal Government awarded $15 million for innovative therapies for mental illness following MMA advocacy. Additional engagement with government sector for policy change and treatment access.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Mind Medicine Australia delivers professional training and treatment-access services for psychedelic-assisted therapies, primarily through its CPAT certification program training clinicians in psilocybin and MDMA protocols, the Fundamentals of PAT online course, and the MMA Clinic providing direct patient treatment for treatment-resistant depression and PTSD. It also operates the Patient Support Fund to subsidise treatment costs and the ANU-hosted PAT Research Registry coordinating clinical trial participation.

Product overview

Mind Medicine Australia operates as a unified platform combining education, treatment access, and research coordination. The core offerings include the Certificate in Psychedelic-Assisted Therapies (CPAT)™ training program and Fundamentals of Psychedelic-Assisted Therapies online course for professional education; MMA Clinic for direct patient treatment; the Patient Support Fund for financial assistance; PAT Research Registry for research coordination; and the CPAT Alumni Directory and Learning Platform for ongoing professional development. These products work together to advance the clinical use of psychedelic-assisted therapies in Australia.

Differentiator

Problem solved

Functional benefit

Brands

• Certificate in Psychedelic-Assisted Therapies (CPAT): World-leading training program for clinicians in psychedelic-assisted therapies
• Patient Support Fund (PSF)
• MMA Clinic

Products and services

• Certificate in Psychedelic-Assisted Therapies (CPAT) A cohort-based professional certification program that trains psychiatrists and therapists in the clinical protocols for psilocybin-assisted and MDMA-assisted therapies, enabling graduates to deliver these treatments under Australia's Schedule 8 framework. Target audience is licensed mental health professionals seeking specialised credentialing.
• Fundamentals of Psychedelic-Assisted Therapies A 6-part online training program covering the science and clinical use of psychedelics, designed to educate medical professionals, mental health professionals, individuals with lived experience, and consumers. Target audience is professionals and lay learners seeking foundational knowledge of psychedelic-assisted therapies.
• MMA Clinic A clinic providing direct patient access to psychedelic-assisted therapies for individuals meeting medical criteria, including treatment for treatment-resistant depression (psilocybin) and PTSD (MDMA). Target audience is patients with treatment-resistant mental health conditions in Australia.
• Patient Support Fund (PSF)

Quantifiable outcome

• Remission rates of 60-80% after just 2-3 treatments when used in combination with psychotherapy
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Cybin: Publicly-traded clinical-stage psychedelic therapeutics company developing psilocybin and deuterated tryptamine programs for depression and anxiety. Direct peer pursuing psychedelic treatment development for similar mental health indications as MMA.
• Multidisciplinary Association for Psychedelic Studies (MAPS): Nonprofit psychedelic research and advocacy organization that led pivotal MDMA-assisted therapy trials for PTSD. Closest peer to MMA's nonprofit training/advocacy/clinic model, with parallel mission to expand access to psychedelic medicine.
• Reunion Neuroscience (formerly Field Trip Health): Former operator of psychedelic therapy clinics (as Field Trip Health) that has transitioned to drug development. Comparable to MMA Clinic's model of directly delivering psychedelic therapy, providing historical precedent for clinic-based psychedelic treatment delivery.
• Fluence: Psychedelic therapy training organization providing professional certification for clinicians in ketamine and psychedelic-assisted therapy. Direct peer to MMA's CPAT program in the therapist training and certification category.
• Compass Pathways: Publicly-traded clinical-stage company developing psilocybin therapy (COMP360) for treatment-resistant depression. Direct peer operating in psychedelic-assisted therapy for similar patient populations, though with a for-profit drug development model rather than MMA's nonprofit training/clinic approach.
• Usona Institute: Nonprofit medical research organization sponsoring psilocybin clinical trials for depression and other conditions. Direct peer to MMA's mission as a nonprofit advancing psychedelic research and treatment access, with similar advocacy-driven model.
• MindMed: Publicly-traded psychedelic medicine biotech developing psychedelic-inspired therapies for mental health. Direct peer in the psychedelic therapy space, focused on anxiety, depression, and addiction indications similar to MMA's treatment targets.
• atai Life Sciences: Publicly-traded clinical-stage biopharma developing psychedelic therapies for mental health, with multiple programs across psilocybin, MDMA, and DMT. Direct peer addressing treatment-resistant depression and PTSD, comparable patient populations to MMA's clinical focus.

Regional players

• Black Dog Institute: Australian medical research institute focused on mental health, with research into psychedelic-assisted therapies. Comparable to MMA as an Australian mental health organization pursuing innovative treatments, though broader in scope beyond psychedelics.

Others

• headspace: Australian National Youth Mental Health Foundation providing mental health services and advocacy. Adjacent to MMA's mission of advancing mental health treatment access in Australia, with comparable nonprofit/advocacy-driven model though focused on youth rather than psychedelic therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/mindmedicineau
• Instagraminstagram.com/mindmedicine.au
• Xx.com/MindMedicineAU
• LinkedInlinkedin.com/company/mind-medicine-australia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mind Medicine Australia